However, convoluted downstream effects greatly complicate perceived clinical potential: increased Ras/Raf/MEK/ERK pathway expression decreases expression of the phosphatase and tensin homolog, contributing to carcinogenesis and prostate tumorigenesis (116, 117). The gene discussed is MAP2K7; the disease is urogenital neoplasm.